JP4716726B2 - 新しいエトノゲストレルエステル - Google Patents

新しいエトノゲストレルエステル Download PDF

Info

Publication number
JP4716726B2
JP4716726B2 JP2004509703A JP2004509703A JP4716726B2 JP 4716726 B2 JP4716726 B2 JP 4716726B2 JP 2004509703 A JP2004509703 A JP 2004509703A JP 2004509703 A JP2004509703 A JP 2004509703A JP 4716726 B2 JP4716726 B2 JP 4716726B2
Authority
JP
Japan
Prior art keywords
etonogestrel
hrt
female
male
decanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004509703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532350A5 (enExample
JP2005532350A (ja
Inventor
デ・ネイス，ヘンリツク
フアン・デル・フオート，ヘンドリクス・アドリアヌス・アントニウス
レイセン，デイルク
フローテンハイス，アリジ・ヤン
Original Assignee
ナームローゼ・フエンノートチヤツプ・オルガノン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナームローゼ・フエンノートチヤツプ・オルガノン filed Critical ナームローゼ・フエンノートチヤツプ・オルガノン
Publication of JP2005532350A publication Critical patent/JP2005532350A/ja
Publication of JP2005532350A5 publication Critical patent/JP2005532350A5/ja
Application granted granted Critical
Publication of JP4716726B2 publication Critical patent/JP4716726B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004509703A 2002-05-30 2003-05-22 新しいエトノゲストレルエステル Expired - Fee Related JP4716726B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02077119.2 2002-05-30
EP02077119 2002-05-30
PCT/EP2003/050187 WO2003102012A2 (en) 2002-05-30 2003-05-22 New etonogestrel esters

Publications (3)

Publication Number Publication Date
JP2005532350A JP2005532350A (ja) 2005-10-27
JP2005532350A5 JP2005532350A5 (enExample) 2006-06-29
JP4716726B2 true JP4716726B2 (ja) 2011-07-06

Family

ID=29595014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004509703A Expired - Fee Related JP4716726B2 (ja) 2002-05-30 2003-05-22 新しいエトノゲストレルエステル

Country Status (30)

Country Link
US (1) US7323454B2 (enExample)
EP (1) EP1513861B1 (enExample)
JP (1) JP4716726B2 (enExample)
KR (1) KR20050009723A (enExample)
CN (2) CN1314701C (enExample)
AR (1) AR040130A1 (enExample)
AT (1) ATE349458T1 (enExample)
AU (1) AU2003238081B2 (enExample)
BR (1) BR0311254A (enExample)
CA (1) CA2487722C (enExample)
CO (1) CO5631449A2 (enExample)
DE (1) DE60310714T2 (enExample)
DK (1) DK1513861T3 (enExample)
ES (1) ES2277085T3 (enExample)
HR (1) HRP20041101A2 (enExample)
IL (1) IL165087A0 (enExample)
IS (1) IS2421B (enExample)
MX (1) MXPA04011797A (enExample)
NO (1) NO20044898L (enExample)
NZ (1) NZ536619A (enExample)
PE (1) PE20040068A1 (enExample)
PL (1) PL373855A1 (enExample)
PT (1) PT1513861E (enExample)
RS (1) RS97604A (enExample)
RU (1) RU2325910C2 (enExample)
SI (1) SI1513861T1 (enExample)
TW (1) TW200403065A (enExample)
UA (1) UA80126C2 (enExample)
WO (1) WO2003102012A2 (enExample)
ZA (1) ZA200410410B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters
ES2691646T3 (es) 2005-07-15 2018-11-28 Micell Technologies, Inc. Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2721832C (en) 2008-04-17 2018-08-07 Micell Technologies, Inc. Stents having bioabsorbable layers
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US20100239635A1 (en) 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
EP3366326A1 (en) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents having controlled elution
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN110269959A (zh) 2013-03-12 2019-09-24 脉胜医疗技术公司 可生物吸收的生物医学植入物
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
RU2595818C1 (ru) * 2015-05-25 2016-08-27 Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" Способ комплексного лечения дисфункции яичников при применении гормонального контрацептива имплантата "импланона"
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB845442A (en) 1956-03-22 1960-08-24 Schering Ag Manufacture of steroid compounds
DE1013284B (de) 1956-03-22 1957-08-08 Schering Ag Verfahren zur Einfuehrung der Reste wenig reaktionsfaehiger Carbonsaeuren, insbesondere des ª‰-Cyclopentyl-propionylrestes, in die 17ª‡-staendige Oxygruppe solcher Steroide, die am Kohlenstoffatom 17 neben der Oxygruppe eine Acetylgruppe tragen
GB8313921D0 (en) 1983-05-19 1983-06-22 World Health Org Contraceptive compositions
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
CN1135716A (zh) * 1993-12-27 1996-11-13 阿克佐诺贝尔公司 经皮吸收的药用制剂
WO1997003709A1 (de) 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
DE19613698A1 (de) 1995-07-17 1997-01-23 Schering Ag Mittel zur transdermalen Applikation enthaltend Ester des 13-Ethyl-17ß-hydroxy-11-methylen-18,19-dinor-17alpha-pregn-4-en-20-yn-3-ons
DE19531936A1 (de) * 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
TR200003743T2 (tr) 1998-06-19 2001-07-23 Akzo Nobel N.V. Testosteron türevi.
WO1999067270A1 (en) 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
US6180682B1 (en) 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters

Also Published As

Publication number Publication date
UA80126C2 (en) 2007-08-27
CA2487722A1 (en) 2003-12-11
CN1314701C (zh) 2007-05-09
RU2325910C2 (ru) 2008-06-10
KR20050009723A (ko) 2005-01-25
IS2421B (is) 2008-10-15
SI1513861T1 (sl) 2007-06-30
CN101100480A (zh) 2008-01-09
ATE349458T1 (de) 2007-01-15
MXPA04011797A (es) 2005-03-31
HRP20041101A2 (en) 2004-12-31
CO5631449A2 (es) 2006-04-28
RS97604A (sr) 2006-10-27
DE60310714D1 (de) 2007-02-08
EP1513861A2 (en) 2005-03-16
BR0311254A (pt) 2005-03-15
CA2487722C (en) 2011-07-19
DE60310714T2 (de) 2007-10-11
WO2003102012A9 (en) 2005-01-13
JP2005532350A (ja) 2005-10-27
US20050222113A1 (en) 2005-10-06
TW200403065A (en) 2004-03-01
WO2003102012A3 (en) 2004-04-22
IS7528A (is) 2004-11-15
PE20040068A1 (es) 2004-02-18
NZ536619A (en) 2007-09-28
ZA200410410B (en) 2006-02-22
US7323454B2 (en) 2008-01-29
WO2003102012A2 (en) 2003-12-11
AU2003238081A1 (en) 2003-12-19
AU2003238081B2 (en) 2008-09-18
ES2277085T3 (es) 2007-07-01
PT1513861E (pt) 2007-03-30
AR040130A1 (es) 2005-03-16
IL165087A0 (en) 2005-12-18
CN1692122A (zh) 2005-11-02
RU2004138807A (ru) 2005-05-27
DK1513861T3 (da) 2007-04-10
NO20044898L (no) 2005-02-25
HK1072609A1 (en) 2005-09-02
PL373855A1 (en) 2005-09-19
EP1513861B1 (en) 2006-12-27

Similar Documents

Publication Publication Date Title
JP2005532350A (ja) 新しいエトノゲストレルエステル
EP1390039A1 (en) Use of estrogen compounds to increase libido in women
RS51640B (sr) 15-supstituisani steroidi sa selektivnom estrogenskom aktivnošću
JP2002518514A (ja) テストステロン誘導体
JP2005532336A (ja) 新規なエトノゲストレルエステルの使用
HK1072609B (en) New etonogestrel esters
HK1072568B (en) Use of new etonogestrel esters
JP2007532688A (ja) １７α−フルオロ−１７β−ヒドロキシイミノメチルステロイド、それらを製造する方法および前記化合物を含んでなる医薬組成物
KR20070061557A (ko) 선택적 에스트로겐 활성을 보이는 15β-치환 스테로이드

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060515

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110105

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110315

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110329

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees